July 19, 2022 7:45am

Volatility is a fearful topic as earnings announcements begin

News: Ultragenyx (RARE) bought GeneTx in a deal that included a $75 million upfront payment and the promise of $115 million to GeneTx shareholders if the Angelman Syndrome therapy hits late-stage clinical and commercial milestones.

Pre-open indications: 2 Positive Indications, 4 Negative Indications and 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.62% or (+193 points), S&P futures are UP +0.78% (+30 points) and NASDAQ futures are UP +0.81% (+97 points) early in the pre-open – so far,


Stock futures rose on Tuesday anticipating a positive open,

European stocks were mixed and uneven anticipating the European Central Bank’s policy meeting in Frankfurt on Thursday,

Asia-Pacific markets mostly lower after the Reserve Bank of Australia released its meeting minutes, which showed that the board saw current rates as being “well below” the neutral rate,



The stock market started the week strong after mixed earnings reports from banks but, began to waive as the afternoon progressed to close down.

The Dow closed DOWN -215.65 points (-0.69%); the S&P closed DOWN -32.31 points (-0.84%) while the Nasdaq closed DOWN -92.37 points (-0.81%)

Side note; “Johnson & Johnson reported better-than-expected quarterly earnings and revenue, although the pharmaceutical giant also cut its full-year revenue and profit guidance.”



RegMed Investors’ (RMi) closing bell: “staring into the abyss as cell and gene therapy sector dives again. Back to that pulsating and nerve-oriented word = sustainability – it should always be in your portfolio’s eye with the caveat “be more careful during uncertain times” - grab any upside while you can. Knew and felt, the downslide was coming”https://www.regmedinvestors.com/articles/12521


Ebb and flow –

Q3/22 – 1 holiday, 4 negative and 7 positive closes

Q2/22 –

June – 1 holiday, 9 positive and 11 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Positive indications:

Sage Therapeutics (SAGE) closed down -$1.07 to $34.18 with a positive +$1.37 or +4.01% pre-open indication,

CRISPR Therapeutics (CRSP) closed down -$4.03 to $79.36 with a positive +$0.65 or +0.82% pre-open indication,


Negative Indications:

Global Blood Therapeutics (GBT) closed down -$1.21 to $34.78 after Friday’s +$1.26 and Thursday’s -$0.60 with a negative -$0.44 or -1.72% pre-open indication,

Verve Therapeutics (VERV) +$2.60 to $26.31 after Friday’s -$0.49 with a negative -$0.31 or -1.18% pre-open indication

Ultragenyx (RARE) closed down -$3.73 to $61.02 with a negative -$2.02 or -3.31% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed flat at $5.00 with 1,319 shares traded after Friday’s -$1.00 to $5.00 with 10.658 shares traded, Thursday’s +$0.12 to $6.00 <52-week low of $1.21>, Wednesday’s +$1.33 to $5.88 with 376 shares traded <3 mo. Average = 1,721 shares> and last Tuesday’s +$0.03 to $4.55 with 175 shares traded.

·         BSTG seems to have the ONLY avenue to finance to utilize non-U.S. Chinese investors?

·         How much lipstick is a lot on this pig with an almost 4-year-old IND and NO clinical trial initiation?

·         WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements as it tries to facilitate an offering with Newbridge Securities



The BOTTOM LINE: I try to keep it simple … and short!

We are up, down, up and down – it gets tiring! Portfolios are wailing, not crying.

Volume Is STILL lower in the sector including both categories – positive moves (10) and negative moves (21) on Monday.

We always need a … villain and they are multiplying – low volume as “Earnings’ season is coming, investors NEED to focus on LPS (loss-per-share), collaboration revenues and cash positions i.e., runways”.

Upcoming earnings announcements: earnings as Alnylam Pharmaceuticals (ALNY) Q2 announcement on Thursday 7/28, Sage Therapeutics (SAGE) on Tuesday, 8/2 and AxoGen (AXGN) on Wednesday, 8/3.

There is VALUE out there however, it’s about playing or betting the timing of the sector.

We are left with choosing to hang on to “our” portfolio position while it is a given that the sector shifts from fierce, sudden sell-offs to gaining altitude or ascending not to its value but, better than it was.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.